bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 3,000 shares of the business’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $180.17, for a total value of $540,510.00. Following the completion of the transaction, the insider now directly owns 27,905 shares of the company’s stock, valued at $5,027,643.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
David Davidson also recently made the following trade(s):
- On Monday, April 2nd, David Davidson sold 22,000 shares of bluebird bio stock. The shares were sold at an average price of $167.52, for a total value of $3,685,440.00.
- On Friday, February 2nd, David Davidson sold 4,000 shares of bluebird bio stock. The shares were sold at an average price of $202.36, for a total value of $809,440.00.
BLUE opened at $170.20 on Tuesday. bluebird bio Inc has a 52-week low of $74.45 and a 52-week high of $236.17. The stock has a market cap of $8,649.65, a P/E ratio of -22.08 and a beta of 2.16.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The company had revenue of $4.17 million for the quarter, compared to the consensus estimate of $7.11 million. During the same quarter in the previous year, the company posted ($1.88) EPS. The business’s revenue was up 169.0% on a year-over-year basis. analysts expect that bluebird bio Inc will post -8.39 EPS for the current fiscal year.
A number of research analysts have issued reports on the company. BTIG Research boosted their target price on bluebird bio to $250.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $250.00 price objective on shares of bluebird bio in a research report on Tuesday, March 13th. Janney Montgomery Scott started coverage on bluebird bio in a research report on Wednesday, March 14th. They set a “neutral” rating and a $220.00 price objective for the company. BidaskClub cut bluebird bio from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 16th. Finally, UBS started coverage on bluebird bio in a research report on Friday, March 16th. They set a “sell” rating for the company. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $195.20.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLUE. Great West Life Assurance Co. Can raised its holdings in bluebird bio by 22.7% during the third quarter. Great West Life Assurance Co. Can now owns 5,531 shares of the biotechnology company’s stock worth $778,000 after acquiring an additional 1,022 shares in the last quarter. Legal & General Group Plc raised its holdings in bluebird bio by 32.4% during the third quarter. Legal & General Group Plc now owns 20,076 shares of the biotechnology company’s stock worth $2,762,000 after acquiring an additional 4,912 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in bluebird bio by 31.8% during the third quarter. Dimensional Fund Advisors LP now owns 139,994 shares of the biotechnology company’s stock worth $19,231,000 after acquiring an additional 33,805 shares in the last quarter. Stifel Financial Corp bought a new stake in bluebird bio during the third quarter worth about $391,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its holdings in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 813 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/17/bluebird-bio-inc-blue-insider-david-davidson-sells-3000-shares-of-stock.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.